Hepatitis C News

Tenofovir alafenamide therapy was safe, well-tolerated and prevented the transmission of hepatitis B virus from pregnant mothers to infants, according to research presented at The Liver Meeting Digital Experience.

Consultations, testing and treatment of hepatitis B and C virus fell significantly during the first year of the COVID-19 pandemic, with many centers seeing declines of more than 75% in all categories, according to a presentation.

Compared to current practices of annual screening for hepatitis C virus in men who have sex with men, working toward reducing their risk and screening every 6 months could prove cost effective, according to a presentation.

Higher end-of-treatment hepatitis B e-antigen level correlated with nucleos(t)ide clinical relapse but did not correlate with relapse severity regardless of HBsAg level among patients with chronic hepatitis B virus, according to research.

Adherence to nurse-led screening programs may be a helpful tool in reducing the risk for liver cancer in patients who have shown sustained virological response after hepatitis C, according to a presenter at UEG Week Virtual.

Authorized generic drugs for insulin and direct-acting antiviral agents may lower out-of-pocket spending for patients but are unlikely to provide savings for Part D plans or Medicare, data show.

Assessing hepatitis D virus patients for viremia, as well as expanded screening for HDV antibodies in hepatitis B virus patients, may help further identify active HDV cases, according to a presentation at UEG Week Virtual.

Because of pandemic-related disruptions in hepatitis C care, researchers said thousands of cases will remain unidentified with fewer patients initiating care and achieving SVR.

WHO released the first-ever global guidance for countries seeking validated hepatitis B virus and hepatitis C virus elimination.

Healio Gastroenterology presents the following report on the top 10 peer-tested stories in July.